Skip to main content

Determining the allogenic platform to generate a safe and efficacious therapyR-T based therapies

25 Jun 2024
Salon B
  • What are the key combination of approaches to reduce the risk of rejection and prevent GVHD?
  • What technologies are required to implement the approaches to help make allogeneic therapies a success?
  • How can we scale up without compromising on the quality of the final product?
Industry Expert
Suchit Sahai, Associate Director - Kite Pharma